RxDoctor Payments Data

Diana Arevalo, MD

Internal Medicine · Mount Kisco, NYNPI 1396841086

Payments from drug & device makers

$3,601in general payments, 2019–2025

Across 96 payments — averaging $37.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Boston Scientific$252
  • Viatris Specialty LLC$162
  • Phathom Pharmaceuticals, Inc.$155
  • GSK$143
  • Sanofi-aventis U.S. LLC$131
  • plus $869 from 14 others

What the payments were for

  • Food & beverage$3,51798%
  • Education$241%
  • Gifts$592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,601 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$69,517
Medicare patients
104
Services billed
1,469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide140$217,028
RybelsusSemaglutide40$83,126
JardianceEmpagliflozin36$56,714
MounjaroTirzepatide34$43,800
EliquisApixaban16$24,837
MyrbetriqMirabegron24$24,439
JanuviaSitagliptin Phosphate26$19,672
Tresiba Flextouch U-100Insulin Degludec16$8,178
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$2,941
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide77$2,826
Atorvastatin Calcium339$2,683
SynthroidLevothyroxine Sodium22$2,151
Rosuvastatin Calcium90$1,492
Gabapentin47$1,471
Valsartan83$1,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,889$300,154180 claims
Boehringer IngelheimJardiance$115$56,71436 claims
Lilly USA, LLCMounjaro$92$43,80034 claims
PfizerEliquis$117$24,83716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Mount Kisco

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →